The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Open Targets Platform: supporting systematic drug–target identification and prioritisation
Open accessAbstract
The Open Targets Platform (https://www.targetvalidation.org/) provides users with a queryable knowledgebase and user interface to aid systematic target identification and prioritisation for drug discovery based upon underlying evidence. It is publicly available and the underlying code is open source. Since our last update two years ago, we have had 10 releases to maintain and continuously improve evidence for target–disease relationships from 20 different data sources. In addition, we have integrated new evidence from key datasets, including prioritised targets identified from genome-wide CRISPR knockout screens in 300 cancer models (Project Score), and GWAS/UK BioBank statistical genetic analysis evidence from the Open Targets Genetics Portal. We have evolved our evidence scoring framework to improve target identification. To aid the prioritisation of targets and inform on the potential impact of modulating a given target, we have added evaluation of post-marketing adverse drug reactions and new curated information on target tractability and safety. We have also developed the user interface and backend technologies to improve performance and usability. In this article, we describe the latest enhancements to the Platform, to address the fundamental challenge that developing effective and safe drugs is difficult and expensive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UniProt: a worldwide hub of protein knowledge
The UniProt Consortium (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1049 · Cited by 7,698
The Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867 · cited 2×
“Many remain stable and provide constant updates for every one of our releases––such as ChEMBL (13), COSMIC (18), Reactome (19), ExpressionAtlas (20), Cancer Gene Census (21) or ePMC (22).”
Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1120 · Cited by 4,000 · cited 1×
“The Open Targets Genetics Portal addresses this problem by interpreting manually curated associations from the GWAS catalog, as well as independent signals from GWAS with publicly available summary statistics, most importantly the UK Biobank GWAS data (7,24,25).”
Self-citationInnovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
The DisGeNET knowledge platform for disease genomics: 2019 update
Piñero, J., Ramírez-Anguita, J. M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., & Furlong, L. I. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1021 · Cited by 2,639 · cited 1×
“Several other resources including Pharos (35), Disgenet (36) or CanSAR (37) given their respective areas of expertise (38).”
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
ChEMBL: towards direct deposition of bioassay data
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P., Nowotka, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1075 · Cited by 2,372
Self-citationThe reactome pathway knowledgebase 2022
Gillespie, M., Jassal, B., Stephan, R., Milacic, M., Rothfels, K., Senff-Ribeiro, A., Griss, J., Sevilla, C., Matthews, L., Gong, C., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1028 · Cited by 2,339
Toxicity Testing in the 21st Century: A Vision and a Strategy
Krewski, D., Acosta, D., Andersen, M., Anderson, H., Bailar, J. C., Boekelheide, K., Brent, R., Charnley, G., Cheung, V. G., Green, S., et al. (2010) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2010.483176 · Cited by 1,688
Cited by
FinnGen provides genetic insights from a well-phenotyped isolated population
Kurki, M. I., Karjalainen, J., Palta, P., Sipilä, T. P., Kristiansson, K., Donner, K. M., Reeve, M. P., Laivuori, H., Aavikko, M., Kaunisto, M. A., et al. (2023) · Nature · doi:10.1038/s41586-022-05473-8 · Cited by 4,233
Search and sequence analysis tools services from EMBL-EBI in 2022
Madeira, F., Pearce, M., Tivey, A. R. N., Basutkar, P., Lee, J., Edbali, O., Madhusoodanan, N., Kolesnikov, A., & Lopez, R. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac240 · Cited by 2,267
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Zhao, J. H., Stacey, D., Eriksson, N., Macdonald-Dunlop, E., Hedman, Å. K., Kalnapenkis, A., Enroth, S., Cozzetto, D., Digby-Bell, J., Marten, J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01588-w · Cited by 747
Mapping the proteo-genomic convergence of human diseases
Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Cortes, A., Koprulu, M., Wörheide, M. A., Oerton, E., Cook, J., Stewart, I. D., Kerrison, N. D., et al. (2021) · Science · doi:10.1126/science.abj1541 · Cited by 657
In silico methods and tools for drug discovery
Shaker, B., Ahmad, S., Lee, J., Jung, C., & Na, D. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104851 · Cited by 607
Stroke genetics informs drug discovery and risk prediction across ancestries
Mishra, A., Malik, R., Hachiya, T., Jürgenson, T., Namba, S., Posner, D. C., Kamanu, F. K., Koido, M., Le Grand, Q., Shi, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05165-3 · Cited by 600
Mountjoy, E., Schmidt, E. M., Carmona, M., Schwartzentruber, J., Peat, G., Miranda, A., Fumis, L., Hayhurst, J., Buniello, A., Karim, M. A., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00945-5 · Cited by 581
Self-citationThe next-generation Open Targets Platform: reimagined, redesigned, rebuilt
Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., Lopez, I., Miranda, A., Cruz-Castillo, C., Fumis, L., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1046 · Cited by 432
Self-citationGroza, T., Gomez, F. L., Mashhadi, H. H., Muñoz-Fuentes, V., Gunes, O., Wilson, R., Cacheiro, P., Frost, A., Keskivali-Bond, P., Vardal, B., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac972 · Cited by 413
Kar, S. P., Quiros, P. M., Gu, M., Jiang, T., Mitchell, J., Langdon, R., Iyer, V., Barcena, C., Vijayabaskar, M. S., Fabre, M. A., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01121-z · Cited by 377
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02143-0 · Cited by 348
“Unlike other target-discovery approaches such as Open Targets 43 or NewDrugTargets 44 , our method was designed and validated to search targets for multiple diseases and aging 15 .”
Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273
Self-citationGrissa, D., Junge, A., Oprea, T. I., & Jensen, L. J. (2022) · Database · doi:10.1093/database/baac019 · Cited by 144
“The latter is also true for knowledge-based aggregators such as Pharos (25) and Open Targets (26), which integrate many types of evidence from numerous sources, including gene–disease associations.”
BackgroundSignificance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer
Yu, J. E., Yeo, I. J., Han, S.-B., Yun, J., Kim, B., Yong, Y. J., Lim, Y.-S., Kim, T. H., Son, D. J., & Hong, J. T. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01131-9 · Cited by 109
AlphaFold illuminates half of the dark human proteins
Binder, J. L., Berendzen, J., Stevens, A. O., He, Y., Wang, J., Dokholyan, N. V., & Oprea, T. I. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102372 · Cited by 81
Mapping the serum proteome to neurological diseases using whole genome sequencing
Png, G., Barysenka, A., Repetto, L., Navarro, P., Shen, X., Pietzner, M., Wheeler, E., Wareham, N. J., Langenberg, C., Tsafantakis, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27387-1 · Cited by 55
Cary, G. A., Wiley, J. C., Gockley, J., Keegan, S., Amirtha Ganesh, S. S., Heath, L., Butler, R. R., Mangravite, L. M., Logsdon, B. A., Longo, F. M., et al. (2024) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12461 · Cited by 49
Tesfaye, M., Jaholkowski, P., Hindley, G. F. L., Shadrin, A. A., Rahman, Z., Bahrami, S., Lin, A., Holen, B., Parker, N., Cheng, W., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01212-4 · Cited by 46
Human genetics uncovers MAP3K15 as an obesity-independent therapeutic target for diabetes
Nag, A., Dhindsa, R. S., Mitchell, J., Vasavda, C., Harper, A. R., Vitsios, D., Ahnmark, A., Bilican, B., Madeyski-Bengtson, K., Zarrouki, B., et al. (2022) · Science Advances · doi:10.1126/sciadv.add5430 · Cited by 36
Varadi, M., Nair, S., Sillitoe, I., Tauriello, G., Anyango, S., Bienert, S., Borges, C., Deshpande, M., Green, T., Hassabis, D., et al. (2022) · GigaScience · doi:10.1093/gigascience/giac118 · Cited by 32
“Proteins are essential building blocks of almost every biological process; therefore, understanding their functions is critical to many applications, from drug discovery [1, 2] to tackling environmental challenges such as plastic pollution [3].”
Somatic mutations alter the differentiation outcomes of iPSC-derived neurons
Puigdevall, P., Jerber, J., Danecek, P., Castellano, S., & Kilpinen, H. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100280 · Cited by 29
Suhre, K., Chen, Q., Halama, A., Mendez, K., Dahlin, A., Stephan, N., Thareja, G., Sarwath, H., Guturu, H., Dwaraka, V. B., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02413-w · Cited by 14
“The Open Targets 27 platform (v.22.10) was used via the API to annotate pQTL variants with most likely causal genes, variant effect, overlapping disease GWAS hits and gene expression, splice variant and proteomics QTLs, ordered by increasing P value and reported separately for cis -QTLs and trans -QTLs.”
InfluentialVaradi, M., Nair, S., Sillitoe, I., Tauriello, G., Anyango, S., Bienert, S., Borges, C., Deshpande, M., Green, T., Hassabis, D., et al. (2022) · doi:10.1101/2022.08.01.501973 · Cited by 2
Metadata
- Authors
- Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Gonzalez-Uriarte, A., Malangone, C., Miranda, A., Fumis, L., Carvalho-Silva, D., Spitzer, M., Baker, J., Ferrer, J., Raies, A., Razuvayevskaya, O., Faulconbridge, A., Petsalaki, E., Mutowo, P., Machlitt-Northen, S., Peat, G., McAuley, E., Ong, C. K., Mountjoy, E., Ghoussaini, M., Pierleoni, A., Papa, E., Pignatelli, M., Koscielny, G., Karim, M., Schwartzentruber, J., Hulcoop, D. G., Dunham, I., & McDonagh, E. M.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-16
- Volume
- 49
- Issue
- D1
- Pages
- D1302-D1310
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W3106143834
- Cited by
- 495
- References
- 38
- FWCI
- 29.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.